publication date: Aug. 8, 2014

html Caris Responses.html

Caris Officials Respond to Questions from The Cancer Letter

The Cancer Letter submitted seven questions to Caris Life Sciences regarding their suite of molecular diagnostic tests, following a conversation with Daniel Hayes (See p. 1), a breast cancer expert at the University of Michigan and who served on an Institute of Medicine committee that recently issued a report on omics testing.

Questions focused on the costs of the tests, who pays for them, and how much of the information they provide is actionable.

Caris is currently involved in lawsuit brought against them by two former employees, who allege that the company violated the federal anti-kickback statute by waiving fees to induce referrals to federal healthcare programs. Caris denies the allegations, and has described the action as a “nuisance lawsuit.”

1.) What is the price of the Caris panel of tests?

We bill on a marker by marker basis based upon the profiling panel requested by the physician and the analytical technology used. This varies by physician and by type of cancer. Ultimately, it is the physician(s) treating the patient that decides which test to order. In common with other companies offering molecular profiling services, the Caris Molecular Intelligence™ (CMI) service is not yet profitable but … Continue reading 40-32 Caris Officials Respond to Questions from The Cancer Letter

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.